Tumor biomarkers for diagnosis, prognosis and targeted therapy DOI Creative Commons
Yue Zhou, Lei Tao, Jiahao Qiu

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Май 20, 2024

Abstract Tumor biomarkers, the substances which are produced by tumors or body’s responses to during tumorigenesis and progression, have been demonstrated possess critical encouraging value in screening early diagnosis, prognosis prediction, recurrence detection, therapeutic efficacy monitoring of cancers. Over past decades, continuous progress has made exploring discovering novel, sensitive, specific, accurate tumor significantly promoted personalized medicine improved outcomes cancer patients, especially advances molecular biology technologies developed for detection biomarkers. Herein, we summarize discovery development including history conventional innovative used biomarker classification biomarkers based on tissue origins, application clinical management. In particular, highlight recent advancements biomarker-based anticancer-targeted therapies emerging as breakthroughs promising strategies. We also discuss limitations challenges that need be addressed provide insights perspectives turn into opportunities this field. Collectively, multiple emphasized review may guidance precision medicine, broaden horizons future research directions, expedite patients according their rather than organs origin.

Язык: Английский

Molecular therapies and precision medicine for hepatocellular carcinoma DOI
Josep M. Llovet, Robert Montal, Daniela Sia

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2018, Номер 15(10), С. 599 - 616

Опубликована: Июль 30, 2018

Язык: Английский

Процитировано

1649
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study DOI
Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque

и другие.

The Lancet Oncology, Год журнала: 2020, Номер 21(5), С. 671 - 684

Опубликована: Март 20, 2020

Язык: Английский

Процитировано

1281
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics DOI Creative Commons

Uttpal Anand,

Abhijit Dey, Arvind K. Singh Chandel

и другие.

Genes & Diseases, Год журнала: 2022, Номер 10(4), С. 1367 - 1401

Опубликована: Март 18, 2022

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions deaths every year. With the new understanding molecular mechanism(s) disease progression, our knowledge about snowballing, leading to evolution many therapeutic regimes their successive trials. In past few decades, various combinations therapies have been proposed are presently employed in treatment diverse cancers. Targeted drug therapy, immunotherapy, personalized medicines now largely being employed, which were not common a years back. The field cancer discoveries therapeutics evolving fast as type-specific biomarkers progressively identified several types cancers nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows targeted approach could be future medicine, chemotherapy remains opted option despite its known side effects on patient's physical psychological health. Chemotherapeutic agents/pharmaceuticals served great purpose over decades remained frontline choice for advanced-stage surgery and/or radiation therapy cannot prescribed due specific reasons. present report succinctly reviews existing contemporary advancements assesses status enrolled drugs/pharmaceuticals; it also comprehensively discusses emerging role specific/targeted strategies achieve better clinical success/survival rate patients.

Язык: Английский

Процитировано

825
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer DOI Creative Commons
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam

и другие.

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Авг. 18, 2023

Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, growth, and cycle progression. Growth factor signalling to transcription factors the PAM axis regulated by multiple cross-interactions with several other pathways, dysregulation of can predispose cancer development. most frequently activated human often implicated resistance anticancer therapies. Dysfunction components this such as hyperactivity PI3K, loss function PTEN, gain-of-function AKT, are notorious drivers treatment disease progression cancer. In review we highlight major dysregulations cancer, discuss results AKT mTOR inhibitors monotherapy co-administation antineoplastic agents clinical trials strategy for overcoming resistance. Finally, mechanisms targeted therapies, including immunology immunotherapies also discussed.

Язык: Английский

Процитировано

823
Angiogenic signaling pathways and anti-angiogenic therapy for cancer DOI Creative Commons

Zhenling Liu,

Huanhuan Chen, Lili Zheng

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Май 11, 2023

Abstract Angiogenesis, the formation of new blood vessels, is a complex and dynamic process regulated by various pro- anti-angiogenic molecules, which plays crucial role in tumor growth, invasion, metastasis. With advances molecular cellular biology, biomolecules such as growth factors, chemokines, adhesion factors involved angiogenesis has gradually been elucidated. Targeted therapeutic research based on these molecules driven treatment to become promising strategy anti-tumor therapy. The most widely used agents include monoclonal antibodies tyrosine kinase inhibitors (TKIs) targeting vascular endothelial factor (VEGF) pathway. However, clinical benefit this modality still limited due several defects adverse events, acquired drug resistance, recurrence, lack validated biomarkers, impel further mechanisms angiogenesis, development multiple drugs combination therapy figure out how improve efficacy. Here, we broadly summarize signaling pathways discuss current challenges We also propose approaches efficacy provide perspective for

Язык: Английский

Процитировано

558
PROTACs: great opportunities for academia and industry DOI Creative Commons
Xiuyun Sun, Hongying Gao, Yiqing Yang

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2019, Номер 4(1)

Опубликована: Дек. 24, 2019

Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem. Another disturbing statistic limited number drug targets, which presently only 20-25% all protein targets that currently being studied. Moreover, focus current explorations their enzymatic functions, ignores functions from scaffold moiety. As promising appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both academia industry for finding available approaches to solve above problems. PROTACs regulate function by degrading target proteins instead inhibiting them, providing more sensitivity drug-resistant greater chance affect nonenzymatic functions. been proven show better selectivity compared classic inhibitors. can be described as chemical knockdown approach with rapidity reversibility, presents new different biology other gene editing tools avoiding misinterpretations arise potential genetic compensation and/or spontaneous mutations. PRTOACs widely explored throughout world outperformed not cancer diseases, but also immune disorders, viral infections neurodegenerative diseases. present very powerful crossing hurdles discovery tool development biology, efforts needed gain get deeper insight into efficacy safety clinic. More binders E3 ligases applicable developing waiting exploration.

Язык: Английский

Процитировано

522
Evolving therapeutic landscape of advanced hepatocellular carcinoma DOI
Chen Yang, Hailin Zhang,

Linmeng Zhang

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2022, Номер 20(4), С. 203 - 222

Опубликована: Ноя. 11, 2022

Язык: Английский

Процитировано

454
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer DOI Creative Commons
Aurélie Cazet, Mun N. Hui, Benjamin Elsworth

и другие.

Nature Communications, Год журнала: 2018, Номер 9(1)

Опубликована: Июль 18, 2018

Abstract The cellular and molecular basis of stromal cell recruitment, activation crosstalk in carcinomas is poorly understood, limiting the development targeted anti-stromal therapies. In mouse models triple negative breast cancer (TNBC), Hedgehog ligand produced by neoplastic cells reprograms cancer-associated fibroblasts (CAFs) to provide a supportive niche for acquisition chemo-resistant, stem (CSC) phenotype via FGF5 expression production fibrillar collagen. Stromal treatment patient-derived xenografts with smoothened inhibitors (SMOi) downregulates CSC markers sensitizes tumors docetaxel, leading markedly improved survival reduced metastatic burden. phase I clinical trial EDALINE, 3 12 patients TNBC derived benefit from combination therapy SMOi Sonidegib docetaxel chemotherapy, one patient experiencing complete response. These studies identify signaling CAFs as novel mediator plasticity an exciting new therapeutic target TNBC.

Язык: Английский

Процитировано

383
Genome-wide association studies of cancer: current insights and future perspectives DOI
Amit Sud, Ben Kinnersley, Richard S. Houlston

и другие.

Nature reviews. Cancer, Год журнала: 2017, Номер 17(11), С. 692 - 704

Опубликована: Окт. 13, 2017

Язык: Английский

Процитировано

353
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer DOI Creative Commons
Luigi Formisano, Yao Lu, Alberto Servetto

и другие.

Nature Communications, Год журнала: 2019, Номер 10(1)

Опубликована: Март 26, 2019

Abstract Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer and transduced were resistant to fulvestrant ± or palbociclib. This resistance was abrogated by treatment FGFR tyrosine kinase (TKI) lucitanib. Addition TKI erdafitinib palbociclib/fulvestrant induced complete responses patient-derived-xenografts. Next generation sequencing circulating tumor DNA (ctDNA) 34 patients after progression on inhibitors FGFR1/2 amplification activating mutations 14/34 (41%) post-progression specimens. Finally, ctDNA from enrolled MONALEESA-2, registration trial ribociclib, showed that exhibited shorter progression-free survival compared wild type FGFR1. Thus, propose cancers pathway alterations should be considered for trials using combinations ER, antagonists.

Язык: Английский

Процитировано

337